Udine, Italy, Oct. 7, 2022 — LimaCorporate announced the FDA approval of a new shoulder platform focused on versatility and Operating Room efficiency. Both the glenoid baseplate and the humeral stem are fully 3D printed, leveraging the long legacy in additive manufacturing. This novel implant system takes advantage of the patented Trabecular Titanium (TT) technology, aiming to guarantee a strong primary fixation and a proven secondary bone ingrowth.
The PRIMA system consists of a novel 3D-printed convertible short stem and a fully 3D-printed glenoid replacement for Reverse Shoulder Arthroplasty.
PRIMA Short Stem is a new addition to the LimaCorporate Shoulder family to satisfy a drive towards greater efficiency in and out of the Operating Room, with its bone preserving fully convertible design allowing simple exchange from anatomic to reverse configuration.
PRIMA TT Glenoid was designed with the ambitious goal of empowering surgeons with a complete solution suitable to solve a wide range of glenoid replacement cases in Reverse Shoulder Arthroplasty. The user can easily move between baseplate designs to address different pathologies from simple primary to complex clinical cases.
Aware that intraoperative experience is one of the major factors influencing surgeons’ practice, the entire development process has been driven by the overarching goal of providing a streamlined surgical technique and instrumentation to support the future users with focus on efficiency and reproducibility.
Massimo Calafiore LimaCorporate CEO stated “Today’s FDA approval for PRIMA TT Glenoid represents an exciting opportunity to accelerate our market growth in key regions. The new PRIMA shoulder platform will support our surgeons to bring the emotion of motion to even more patients!”.